petiteblanche
Lv4
440 积分
2024-01-18 加入
-
Learning from clinical trials of neoadjuvant checkpoint blockade
24天前
已完结
-
Immune checkpoint inhibitors induced side effects of the peripheral nervous system
1个月前
已完结
-
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
1个月前
已完结
-
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
1个月前
已完结
-
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
1个月前
已完结
-
Association Between Duration of Immunotherapy and Overall Survival in Advanced Non–Small Cell Lung Cancer
1个月前
已完结
-
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
1个月前
已完结
-
First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826
3个月前
已完结
-
Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
3个月前
已完结